Q: Knight is rising nicely today following a marginal pullback. Is this a bet that the healthcare bill won't pass as it may create more opportunity for the purchase of distressed products?
Thanks.
Thanks.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: The CEO just made a large purchase of shares. Do you think this is a vote of confidence in the company?
Q: What are your views on IMM. Thanks Ted
Q: Thanks for your informative and useful service. I read yesterday that Oncolytics is collaborating with Celgene on a Phase 1b trial. Is this a game changer or just more of the same. Nigel
Q: Would appreciate a comment on yesterday's earnings and the possibility of their running out of money in 12 months.
Q: If you had to choose only one and looking for capital appreciation,which would you choose?
Q: Hello, today the Amgen stock has closed down by 6.50%. Could you explain the reason(s)for that? Regards, Gervais
Q: I bought CRH at 4 dollars. It's now at app. 11 dollars. In the past with CCL and CSU, as the stocks ran up I trimmed and took profits. In hindsight, I would have done better if I had let them both run.
What I've learned from you is that picking a weight you're comfortable with is the best way to go. CRH now represents app. 7% of my portfolio. What is your recommendation as to the maximum weight for any one stock?
Thanks for the great service. cheers
Andy
What I've learned from you is that picking a weight you're comfortable with is the best way to go. CRH now represents app. 7% of my portfolio. What is your recommendation as to the maximum weight for any one stock?
Thanks for the great service. cheers
Andy
Q: Mr. Hodson, on March 6, 2017, I bought GUD at 10.73. But It started to slide, and I sold it with a loss. It is now at 10.37 and I am reluctant to re-enter.
Advisable to do so when it gets to is former high of 11.03 ?
Advisable to do so when it gets to is former high of 11.03 ?
Q: How were the earnings ? Buy more ?
Q: There are several health care funds that pay high yield but seem to trade lightly.Is there a lot of uncertainty to them,they seem unloved.Is there any that would seem ok for income and slight growth ?
Q: Hi Peter and Team,
Could you please comment on CXR quarter result and future of company going forward.
Thanks
Could you please comment on CXR quarter result and future of company going forward.
Thanks
Q: I have owned CRH from around $3.00. After it doubled i sold half my position. It has now almost doubled again. I am not overweight the name but would it be wise to reduce it to a half position now as it seems to have run up so quickly? Basically should i be locking in some gains or do you have confidence it will perform in the medium term?
Q: Hi, I just read Bob's question about Savaria and the Chinese Market, I'm wondering what your thoughts might be on the possibility that the Chinese market is very good at reverse engineering things and they in fact could be a competitor in the future.
I really appreciate your services, Thank You
I really appreciate your services, Thank You
Q: I would appreciate your comments on Biosyent's quarterly and full year earnings report issued this morning.
Thank you, Peter
Thank you, Peter
Q: I noticed that the estimated earnings for this quarter for GUD are slightly lower than the same quarter for last year. Are earnings for GUD usually lumpy?
Q: I noticed that it has been nearly 4 years since you last commented on this company so I would appreciate it if you could provide an update.
Keep up the great work.
Keep up the great work.
Q: Can you comment on its latest acquisition. Thx
Q: Can you please comment on recent earnings? Is it time to get out of the stock?
Q: My question is about ARRY. I know the company is out of your wheel-house, but wondering if you have any opinions on them. Should I do some profit-taking or hold for the longer term. Friday seemed like a bad day for the stock for whatever reason, but this is not a reaction to that.
Cheers
Cheers